We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer (ISA-P53-CTX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00844506
Recruitment Status : Completed
First Posted : February 16, 2009
Last Update Posted : February 25, 2011
ISA Pharmaceuticals B.V.
Dutch Cancer Society
Information provided by:
University Medical Center Groningen

Brief Summary:
The purpose of this study is to determine whether the addition of cyclophosphamide to the treatment with the p53-SLP vaccine improves clinical efficacy and immunogenicity of the p53-SLP vaccine in ovarian cancer patients.

Condition or disease Intervention/treatment Phase
Ovarian Cancer Drug: P53-SLP vaccine Drug: Cyclophosphamide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 19 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer a Phase II Trial
Study Start Date : October 2008
Actual Primary Completion Date : July 2009
Actual Study Completion Date : July 2009

Intervention Details:
  • Drug: P53-SLP vaccine
    The P53-SLP vaccine is a vaccine consisting of a total of 10 long (30 amino acids on average length) peptides, covering the p53 protein sequence from amino acid 70 to 251, combined with Montanide ISA51 an adjuvant with a sustained dendritic cell activating ability. Patients will be immunised subcutaneously with the peptide vaccine four times with a three week interval (300μg/peptide).
  • Drug: Cyclophosphamide
    Two days prior to each peptide vaccination, patients will receive 300mg/m2 cyclophosphamide i.v.
    Other Names:
    • Endoxan
    • Cytoxan

Primary Outcome Measures :
  1. Clinical responses to the p53 synthetic long peptide vaccine preceded by cyclophosphamide will be assessed by measurement of serum CA-125 levels and CT-scan. [ Time Frame: day 105 - 126 after first gift of cyclophosphamide ]
  2. Immunogenicity will be evaluated by assessing induction and frequency of p53-specific T cells by proliferation and IFN-γ ELISPOT. [ Time Frame: after fourth immunization ]

Secondary Outcome Measures :
  1. Safety of the vaccine preceded by cyclophosphamide will be assessed by monitoring the incidence and severity of adverse events using Common Terminology Criteria for Adverse Events v3.0. [ Time Frame: durante study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent.
  • Histological proven epithelial ovarian carcinoma.
  • At least 4 weeks after termination of the last course of chemotherapy.
  • Rising CA-125 serum levels after "first line" treatment and no measurable disease according to the RECIST (Response Evaluation Criteria in Solid Tumours) criteria, or Rising CA-125 serum levels after "first line" treatment with measurable disease according to the RECIST (Response Evaluation Criteria in Solid Tumours) criteria, but not willing or otherwise not fit to receive "second line" chemotherapy.
  • Age 18 years or older, and an life expectancy of at least 3 months.
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
  • Performance status 0 to 2 (WHO scale).
  • Adequate hepatic, renal, and bone marrow function as defined:

ASAT < 100 U/l; ALAT < 113 U/l; PT 9-12 seconds; APTT 23-33 seconds; creatinine < 135 μmol/l; WBC > 3.0 x 109/L; platelets > 100 x 109/L; hemoglobin > 6.0 mmol/l.

- Adequate venous access for blood collection and i.v. administration of cyclophosphamide.

Exclusion Criteria:

  • Pregnancy and / or breast feeding.
  • (A)symptomatic cystitis.
  • Other malignancies (previous or current), except basal or squamous cell carcinoma of the skin.
  • Immunosuppressive agents, except for topical and inhalation corticosteroids.
  • Prior therapy with a biological response modifier.
  • Any other major disease that may interfere with the conduct of the study (e.g. uncontrolled hypertension, severe and/or unstable heart disease, neurological and psychiatric disorders).
  • Signs or symptoms of CNS metastases.
  • Known substance abuse (drug or alcohol).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00844506

Layout table for location information
University Medical Centre Groningen
Groningen, Netherlands, 9700 RB
Sponsors and Collaborators
University Medical Center Groningen
ISA Pharmaceuticals B.V.
Dutch Cancer Society
Layout table for investigator information
Principal Investigator: H. W. Nijman, MD University Medical Center Groningen
Layout table for additonal information
Responsible Party: Prof. Dr. H.W. Nijman, University Medical Centre Groningen
ClinicalTrials.gov Identifier: NCT00844506    
Other Study ID Numbers: ISA-P53-CTX
EUDRACT 2007-007734-19
CCMO NL21308.000.07
First Posted: February 16, 2009    Key Record Dates
Last Update Posted: February 25, 2011
Last Verified: February 2011
Keywords provided by University Medical Center Groningen:
Ovarian cancer patients with recurrent disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists